The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease
Open accessAbstract
Introduction: Alzheimer's disease (AD) and Parkinson's disease (PD) involve tau pathology. Tau is detectable in blood, but its clearance from neuronal cells and the brain is poorly understood. Methods: Tau efflux from the brain to the blood was evaluated by administering radioactively labeled and unlabeled tau intracerebroventricularly in wild‐type and tau knock‐out mice, respectively. Central nervous system (CNS)–derived tau in L1CAM‐containing exosomes was further characterized extensively in human plasma, including by single molecule array technology with 303 subjects. Results: The efflux of Tau, including a fraction via CNS‐derived L1CAM exosomes, was observed in mice. In human plasma, tau was explicitly identified within L1CAM exosomes. In contrast to AD patients, L1CAM exosomal tau was significantly higher in PD patients than controls and correlated with cerebrospinal fluid tau. Conclusions: Tau is readily transported from the brain to the blood. The mechanisms of CNS tau efflux are likely different between AD and PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The rationale for using plasma biomarkers as proxies for brain processes [173] has been demonstrated for multiple neurodegenerative diseases [174, 175].”
From Systems-based proteomics to resolve the biology of Alzheimer’s disease beyond amyloid and tau (2021) · cites this paper as [175]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rissin, D. M., Kan, C. W., Campbell, T. G., Howes, S. C., Fournier, D. R., Song, L., Piech, T., Patel, P. P., Chang, L., Rivnak, A. J., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1641 · Cited by 2,119
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Genome-wide association study reveals genetic risk underlying Parkinson's disease
Simón-Sánchez, J., Schulte, C., Bras, J. M., Sharma, M., Gibbs, J. R., Berg, D., Paisan-Ruiz, C., Lichtner, P., Scholz, S. W., Hernandez, D. G., et al. (2009) · Nature Genetics · doi:10.1038/ng.487 · Cited by 1,751
Sizing and phenotyping of cellular vesicles using Nanoparticle Tracking Analysis
Dragovic, R., Gardiner, C., Brooks, A. S., Tannetta, D., Ferguson, D. J. P., Hole, P., Carr, B., Redman, C. W. G., Harris, A. L., Dobson, P. J., et al. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.04.003 · Cited by 1,368
Tau pathology and neurodegeneration
Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133
Fiandaca, M. S., Kapogiannis, D., Mapstone, M., Boxer, A., Eitan, E., Schwartz, J. B., Abner, E. L., Petersen, R. C., Federoff, H. J., Miller, B. L., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.008 · Cited by 959
Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease
Shi, M., Liu, C., Cook, T. J., Bullock, K. M., Zhao, Y., Ginghina, C., Li, Y., Aro, P., Dator, R., He, C., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1314-y · Cited by 676
Self-citationDJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease
Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., et al. (2010) · Brain · doi:10.1093/brain/awq008 · Cited by 615
Self-citationEdwards, T. L., Scott, W. K., Almonte, C., Burt, A., Powell, E. H., Beecham, G. W., Wang, L., Zuchner, S. L., Konidari, I., Wang, G., et al. (2010) · Annals of Human Genetics · doi:10.1111/j.1469-1809.2009.00560.x · Cited by 471
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression
Shi, M. Y., Bradner, J. M., Hancock, A. M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J. J., Zabetian, C. P., Kim, H. M., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22311 · Cited by 422
Self-citation
Research works printed but not linked: 1
- Davson H, 1996, The return of the cerebrospinal fluid to the blood: the drainage mechanism. Physiology of the CSF and blood‐brain barriers, 489
Cited by
Sorted by citations
Exosome Processing and Characterization Approaches for Research and Technology Development
Lai, J. J., Chau, Z. L., Chen, S., Hill, J. J., Korpany, K. V., Liang, N., Lin, L., Lin, Y., Liu, J. K., Liu, Y., et al. (2022) · Advanced Science · doi:10.1002/advs.202103222 · Cited by 623
Banks, W. A., Sharma, P., Bullock, K. M., Hansen, K. M., Ludwig, N., & Whiteside, T. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124407 · Cited by 561
“An efflux system would explain why CNS-derived exosomes are found in the circulation [7], raising the question of their role in disease states and supporting their usefulness as biomarkers of CNS diseases.”
BackgroundInfluentialSelf-citationPromoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing
Boland, B., Yu, W. H., Corti, O., Mollereau, B., Henriques, A., Bézard, E., Pastores, G., Rubinsztein, D. C., Nixon, R. A., Duchen, M. R., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.109 · Cited by 566
Cell-cell communication: New insights and clinical implications
Su, J., Song, Y., Zhu, Z., Huang, X., Fan, J., Qiao, J., & Mao, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01888-z · Cited by 433
L1CAM is not associated with extracellular vesicles in human cerebrospinal fluid or plasma
Norman, M., Ter‐Ovanesyan, D., Trieu, W., Lazarovits, R., Kowal, E. J. K., Lee, J.-H., Chen‐Plotkin, A. S., Regev, A., Church, G. M., & Walt, D. R. (2021) · Nature Methods · doi:10.1038/s41592-021-01174-8 · Cited by 261
Metadata
- Authors
- Shi, M., Kovac, A., Korff, A., Cook, T. J., Ginghina, C., Bullock, K. M., Yang, L., Stewart, T., Zheng, D., Aro, P., Atik, A., Kerr, K. F., Zabetian, C. P., Peskind, E. R., Hu, S., Quinn, J. F., Galasko, D. R., Montine, T. J., Banks, W. A., & Zhang, J.
- Affiliations
- University of Washington (US)
- Geriatric Research, Education, and Clinical Center Veterans Affairs Puget Sound Health Care System Seattle WA USA
- Department of Pathology University of Washington School of Medicine Seattle WA USA
- Oregon Health & Science University (US)
- University of California San Diego (US)
- Corresponding author
- Zhang, Jing
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2016-05-24
- Volume
- 12
- Issue
- 11
- Pages
- 1125-1131
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- PMC
- PMC5107127
- OpenAlex
- W2398356848
- Cited by
- 206
- References
- 29
- Citations by year
- 2026: 8 · 2025: 15 · 2024: 29 · 2023: 27 · 2022: 29 · 2021: 24 · 2020: 31 · 2019: 16 · 2018: 17 · 2017: 6 · 2016: 4
- FWCI
- 11.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Alzheimer s & Dementia (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (U01 NS082137, P30 ES007033‐6364, R01 AG033398, R01 ES016873, R01 ES019277, R01 NS057567, P50 NS062684‐6221, R21 NS085425, R01 NS065070, P50 AG05131)
- Alzheimer's Association (2015‐NIRG‐342009)
- U.S. Department of Veterans Affairs
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- tau protein
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alzheimer Disease, Animals, Biological Transport, Blood-Brain Barrier, Female, Humans, Male, Mice, Inbred C57BL, Middle Aged, Parkinson Disease, tau Proteins, Mice, Knockout, Neural Cell Adhesion Molecule L1, Exosomes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
